Table 1. Characteristics of patient and control study population used to measure CSF sTREM2.

Data are expressed as number of patients (percent), mean ± SD, or median (IQR) as appropriate. Probability values (P) denote differences between control, AD, and FTD patient groups. χ2 tests were used for gender. One-way analysis of variance (ANOVA) was used to compare age between groups followed by Tukey post hoc test. CSF biomarkers and sTREM2 were evaluated by nonparametric statistical analysis (Kruskal-Wallis and post hoc with Mann-Whitney U test).

VariableTotal (n = 194)Control (n = 88)AD (n = 56)FTD (n = 50)P
Gender (F/M), no. (%)113 (58)/81 (42)55 (63)/33 (37)38 (68)/18 (32)20 (40)/30 (60)0.008*
Age, years (mean ± SD)64.6 ± 10.160.7 ± 9.570.4 ± 8.965.0 ± 9.4<0.001
CSF biomarkers
  Aβ1–42 (pg/ml), median (IQR)640.5 (460–824)779.3 (643–914)416.5 (312–526)640.3 (491–829)<0.001
  T-tau (pg/ml), median (IQR)254.7 (175–498)204.3 (153–242)665.3 (492–910)256.1 (203–356)<0.001§
  P-tau181P (pg/ml), median (IQR)46.5 (37–69)39.5 (35–50)88.3 (67–103)40.8 (30–51)<0.001
sTREM2 (relative units)
  Median (IQR)0.323 (0.201–0.448)0.381 (0.283–0.518)0.309 (0.178–0.436)0.231 (0.180–0.370)<0.001

*Post hoc significances for gender: controls versus AD, P = 0.512; controls versus FTD, P = 0.011; AD versus FTD, P = 0.004.

†Post hoc significances for age: controls versus AD, P < 0.001; controls versus FTD, P = 0.025; AD versus FTD, P = 0.009.

‡Post hoc significances for Aβ1–42: controls versus AD, P < 0.001; controls versus FTD, P = 0.001; AD versus FTD, P < 0.001.

§Post hoc significances for T-tau: controls versus AD, P < 0.001; controls versus FTD, P < 0.001; AD versus FTD, P < 0.001.

¶Post hoc significances for P-tau181P: controls versus AD, P < 0.001; controls versus FTD, P = 0.865; AD versus FTD, P < 0.001.

∥Post hoc significances for sTREM2: controls versus AD, P = 0.001; controls versus FTD, P < 0.001; AD versus FTD, P = 0.271.